Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivotal Phase 2 Study of Ponatinib in Refractory CML and Ph+ ALL
2010-020414-28Phase 2Completed
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), sponsored by ARIAD Pharmaceuticals, Inc. Primary endpoint: Major cytogenetic response in chronic phase CML. Started Dec 2010; status: completed.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2010-020414-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020414-28.